Facebook
Twitter
Telegram
Report an ErrorXBiotech Balance Sheet 2011-2024 | XBIT
Annual Balance Sheet XBiotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -237 M | -715 M | -15.8 M | -31.8 M | -34.3 M | -91.1 M | -57.3 M | -7.24 M | -4.17 M | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 1.12 M | 1.06 M | 3 K | 18 K | 23 K | 17 K | - | - | 30 K | - |
Total Current Liabilities |
6.1 M | 4.07 M | 3.45 M | 3.98 M | 60.2 M | 2.94 M | 2.79 M | 7.96 M | 6.29 M | 3.15 M | - | - | - |
Total Liabilities |
7.77 M | 5.7 M | 5.79 M | 5.1 M | 61.2 M | 2.95 M | 2.81 M | 7.99 M | 6.31 M | 3.15 M | 845 K | 1.1 M | - |
Deferred Revenue |
- | - | - | - | 4.5 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-52.3 M | -27.7 M | 5.15 M | 97.6 M | 431 M | -238 M | -217 M | -183 M | -131 M | -93.2 M | -71.4 M | -61.5 M | - |
Total Assets |
227 M | 246 M | 275 M | 354 M | 817 M | 44.3 M | 63 M | 67 M | 109 M | 62.2 M | 11.1 M | 8.47 M | - |
Cash and Cash Equivalents |
200 M | 157 M | 237 M | 237 M | 715 M | 15.8 M | 31.8 M | 34.3 M | 91.1 M | 57.3 M | 7.24 M | 4.17 M | - |
Book Value |
219 M | 240 M | 269 M | 349 M | 756 M | 41.4 M | 60.2 M | 59.1 M | 103 M | 59 M | 10.2 M | 7.37 M | - |
Total Shareholders Equity |
219 M | 240 M | 269 M | 349 M | 756 M | 41.4 M | 60.2 M | 59.1 M | 103 M | 59 M | 10.2 M | 7.37 M | - |
All numbers in USD currency
Quarterly Balance Sheet XBiotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.94 M | 6.07 M | 5.22 M | 5.7 M | 6.02 M | 10.7 M | 5.24 M | 5.79 M | 5.36 M | 5.39 M | 3.84 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 61.2 M | 61.2 M | 61.2 M | 61.2 M | 2.95 M | 2.95 M | 2.95 M | 2.95 M | 2.81 M | 2.81 M | 2.81 M | 2.81 M | 7.99 M | 7.99 M | 7.99 M | 7.99 M | 6.31 M | 6.31 M | 6.31 M | 6.31 M | 3.15 M | 3.15 M | 3.15 M | 3.15 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.5 M | 4.5 M | 4.5 M | 4.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-47.7 M | -40.3 M | -31.6 M | -27.7 M | -24.5 M | -11.9 M | -244 K | 5.15 M | 11.6 M | 89.9 M | 95 M | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 431 M | 431 M | 431 M | 431 M | -238 M | -238 M | -238 M | -238 M | -217 M | -217 M | -217 M | -217 M | -183 M | -183 M | -183 M | -183 M | -131 M | -131 M | -131 M | -131 M | -93.2 M | -93.2 M | -93.2 M | -93.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
230 M | 235 M | 242 M | 246 M | 251 M | 266 M | 271 M | 275 M | 280 M | 354 M | 356 M | 354 M | 354 M | 354 M | 354 M | 817 M | 817 M | 817 M | 817 M | 44.3 M | 44.3 M | 44.3 M | 44.3 M | 63 M | 63 M | 63 M | 63 M | 67 M | 67 M | 67 M | 67 M | 109 M | 109 M | 109 M | 109 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
202 M | 143 M | 152 M | 157 M | 161 M | 226 M | 232 M | 237 M | 239 M | 315 M | 240 M | 237 M | 237 M | 237 M | 237 M | 715 M | 715 M | 715 M | 715 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 91.1 M | 91.1 M | 91.1 M | 91.1 M | 57.3 M | 57.3 M | 57.3 M | 57.3 M | 7.24 M | - | - | - | 4.17 M | - | - | - | - | - | - | - |
Book Value |
223 M | 229 M | 237 M | 240 M | 245 M | 256 M | 266 M | 269 M | 274 M | 349 M | 352 M | 349 M | 349 M | 349 M | 349 M | 756 M | 756 M | 756 M | 756 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 60.2 M | 60.2 M | 60.2 M | 60.2 M | 59.1 M | 59.1 M | 59.1 M | 59.1 M | 103 M | 103 M | 103 M | 103 M | 59 M | 59 M | 59 M | 59 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
223 M | 229 M | 237 M | 240 M | 245 M | 256 M | 266 M | 269 M | 274 M | 349 M | 352 M | 349 M | 349 M | 349 M | 349 M | 756 M | 756 M | 756 M | 756 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 60.2 M | 60.2 M | 60.2 M | 60.2 M | 59.1 M | 59.1 M | 59.1 M | 59.1 M | 103 M | 103 M | 103 M | 103 M | 59 M | 59 M | 59 M | 59 M | 10.2 M | - | - | - | 7.37 M | - | - | - | - | - | - | - |
All numbers in USD currency